Modern concepts of antimicrobial therapy regimens for exacerbation of chronic obstructive pulmonary disease: A review

Cover Page

Cite item

Full Text

Abstract

The publication discusses modern antimicrobial therapy regimens in patients with exacerbation of chronic obstructive pain. Lung diseases from the perspective of the updated version of national recommendations. Indications for prescribing antibiotics, etiological exacerbation risk factors, risk factors for encountering microorganisms with antibiotic resistance mechanisms, selection algorithm antimicrobial drug.

About the authors

Andrey A. Zaytsev

Burdenko Main Military Clinical Hospital; BIOTECH University

Email: a-zaicev-a@yandex.ru
ORCID iD: 0000-0002-0934-7313

D. Sci. (Med.), Prof., Burdenko Main Military Clinical Hospital, BIOTECH University

Russian Federation, Moscow; Moscow

Igor V. Leshchenko

Ural State Medical University; Ural Research Institute of Phthisiopulmonology – branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases

Author for correspondence.
Email: leshchenkoiv@yandex.ru

D. Sci. (Med.), Ural State Medical University, Ural Research Institute of Phthisiopulmonology – branch of the National Medical Research Center for Phthisiopulmonology and Infectious Diseases

Russian Federation, Yekaterinburg; Yekaterinburg

References

  1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2023. Available at: http://www.goldcopd.org/ Accessed: 15.08.2023.
  2. Roche N, Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat. 2004;54(13):1408-13.
  3. Клинические рекомендации. Хроническая обструктивная болезнь легких, 2023 (проект). Режим доступа: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf. Ссылка активна на 15.08.2023 [Clinical recommendations. Chronic obstructive pulmonary disease, 2023 (project). Available at: https://spulmo.ru/upload/kr/HOBL_2023_draft.pdf. Accessed: 15.08.2023 (in Russian)].
  4. The top 10 causes of death. Available at: http://www.who.int/mediacentre/factsheets/fs310/en/ Accessed: 15.08.2023.
  5. Donaldson G, Seemungal T, Bhowmik A, Wedzicha J. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52.
  6. Soler-Cataluña J, Martínez-García M, Román Sánchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;64:925-31.
  7. Celli B, MacNee W. ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Am J Respir Crit Care Med. 2021;204(11):1251-8.
  8. Синопальников А.И., Зайцев А.А. Комплаентность пациентов с инфекциями дыхательных путей. Клиническая микробиология и антимикробная химиотерапия. 2008;1:50-9 [Sinopalnikov AI, Zaitsev AA. Patient compliance with antimicrobial therapy of lower respiratory tract infections. Klinicheskaia mikrobiologiia I anrimikrobnaia khimioterapiia. 2008;1:50-9 (in Russian)].
  9. Зайцев А.А., Синопальников А.И. Рациональная фармакотерапия острых респираторных вирусных инфекций. Consilium Medicum. 2008;10:80-6 [Zaitsev AA, Sinopal'nikov AI. Ratsional'naia farmakoterapiia ostrykh respiratornykh virusnykh infektsii. Consilium Medicum. 2008;10:80-6 (in Russian)].
  10. Anthonisen N, Manfreda J, Warren C, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196-204.
  11. Almirall J, Bolíbar I, Toran P, et al. Contribution of C-reactive protein to the diagnosis and assessment of severity of community-acquired pneumonia. Chest. 2004;125:1335-42.
  12. Bafadhel M, Clark T, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest. 2011;139(6):1410-7.
  13. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Уральский медицинский журнал. 2008;13:19-24 [Avdeev SN, Baimakanova GE, Zubairova PA. Vozmozhnosti S-reaktivnogo belka v diagnostike bakterial'noi infektsii i pnevmonii u bol'nykh s obostreniem khronicheskoi obstruktivnoi bolezni legkikh. Ural'skii meditsinskii zhurnal. 2008;13:19-24 (in Russian)].
  14. Ruiz-González A, Sáez-Huerta E, Martinez-Alonso M, et al. A Simple Scoring System to Differentiate Bacterial from Viral Infections in Acute Exacerbations of COPD Requiring Hospitalization Int. J Cron Obstruct Pulmon Dis. 2022;17:773-9. doi: 10.2147/COPD.S356950
  15. Sethi S, Murphy T. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. 2008;359:2355.
  16. Diederen B, van der Valk P, Kluytmans J, et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007;30:240-4.
  17. Guggenbichler J, Kastner H. The influence of macrolide antibiotics on the fecal and oral flora. Infect Med. 1998;15:17-25.
  18. Hardy DJ, Swanson RN, Rode PA, et al. Enhancement of the In Vitro and In Vivo Activities of Clarithromycin against Haemophilus influenzae by 14-Hydroxy-Clarithromycin, Its Major Metabolite in Humans. Antimicrob Agents Chemother. 1990;34:1407-13.
  19. Козлов Р.С., Дехнич А.В. Цефдиторен пивоксил: клинико-фармакологическая и микробиологическая характеристика. Клиническая микробиология и антимикробная химиотерапия. 2014;2:111-29 [Kozlov RS, Dekhnich АV. Cefditoren pivoxil: clinical, pharmacological, and microbiological aspects. Klinicheskaia mikrobiologiia i antimikrobnaiia khimioterapiia. 2014;2:111-29 (in Russian)].
  20. Giménez M, Aguilar L, José Granizo J. Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults. Multidisciplinary Resp Med. 2018;13:40. doi: 10.1186/s40248-018-0152-5
  21. Miyazaki T, Fukushima K, Hashiguchi K, et al. Efficacy and safety of cefditoren pivoxil for exacerbations of chronic obstructive pulmonary disease: A prospective multicenter interventional study. J Infect Chemother. 2019;25(9):702-7.
  22. Alvarez-Sala JL, Karlos P, Martinez-Beltran J, et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob Agents Chemother. 2006;50(5):1762-7. doi: 10.1128/AAC.50.5.1762-1767.2006
  23. Canut A, Martin-Herrero J, Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? Therapeutic outcomes model. J Antimicrob Chemother. 2007;60:605-62.
  24. Falagas M, Avgeri S, Matthaiou D, Dimopoulos G. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. J Antimicrob Chemother. 2008;62(3):442-50.
  25. Lorenz J, Steinfeld P, Drath L, et al. Efficacy and Tolerability of 5- vs 10-Day Cefixime Therapy in Acute Exacerbations of Chronic Bronchitis. Clin Drug Investig. 1998;15(1):13-20.
  26. Chodosh S, DeAbate C, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med. 2000;94:18-27.
  27. Козлов Р.С., Авдеев С.Н., Брико Н.И., и др. Вакцинопрофилактика пневмококковых инфекций у взрослых. Резолюция совета экспертов (Москва, 16 декабря 2017 г.). Клиническая микробиология и антимикробная химиотерапия. 2018;20(1):5-8 [Kozlov RS, Avdeev SN, Briko NI. Vaccination against pneumococcal infections in adults. Klinicheskaia mikrobiologiia i antimikrobnaiia khimioterapiia. 2018;20(1):5-8 (in Russian)].
  28. Синопальников А.И., Зайцев А.А. Современный взгляд на фармакотерапию обострений хронической обструктивной болезни легких. Лечащий врач. 2009;10:45-9 [Sinopal'nikov AI, Zaitsev AA. Sovremennyi vzglyad na farmakoterapiiu obostrenii khronicheskoi obstruktivnoi bolezni legkikh. Lechashchii vrach. 2009;10:45-9 (in Russian)].
  29. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;1:CD002733.
  30. Cazzola M. A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD. A double-blind, randomized, placebo-controlled trial. Trends Med. 2006;6(3):199-207.
  31. Huang Y, Pei Y, Qian Y, et al. A meta-analysis on the Efficacy and Safety of Bacterial Lysates in Chronic Obstructive Pulmonary Disease. Front Med (Lausanne). 2022;9:977124. doi: 10.3389/fmed.2022.877124

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Classification of severity of exacerbation of COPD [3].

Download (340KB)
Indexing metadata
3. Fig. 2. Stratification of exacerbations of COPD [10].

Download (89KB)
Indexing metadata

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies